Journal article
Serum IgG and mucosal IgA antibodies from pre-pandemic samples collected in Kilifi, Kenya, neutralize SARS-CoV-2 in vitro
- Abstract:
-
Objectives
Many regions of Africa have experienced lower COVID-19 morbidity and mortality than Europe. Pre-existing humoral responses to endemic human coronaviruses (HCoV) may cross-protect against SARS-CoV-2. We investigated the neutralizing capacity of SARS-CoV-2 spike reactive and nonreactive immunoglobulin (Ig)G and IgA antibodies in prepandemic samples.
Methods
To investigate the presence of pre-existing immunity, we performed enzyme-linked immunosorbent assay using spike antigens from reference SARS-CoV-2, HCoV HKU1, OC43, NL63, and 229E using prepandemic samples from Kilifi in coastal Kenya. In addition, we performed neutralization assays using pseudotyped reference SARS-CoV-2 to determine the functionality of the identified reactive antibodies.
Results
We demonstrate the presence of HCoV serum IgG and mucosal IgA antibodies, which cross-react with the SARS-CoV-2 spike. We show pseudotyped reference SARS-CoV-2 neutralization by prepandemic serum, with a mean infective dose 50 of 1: 251, which is 10-fold less than that of the pooled convalescent sera from patients with COVID-19 but still within predicted protection levels. The prepandemic naso-oropharyngeal fluid neutralized pseudo-SARS-CoV-2 at a mean infective dose 50 of 1: 5.9 in the neutralization assay.
Conclusion
Our data provide evidence for pre-existing functional humoral responses to SARS-CoV-2 in Kilifi, coastal Kenya and adds to data showing pre-existing immunity for COVID-19 from other regions.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 936.0KB, Terms of use)
-
- Publisher copy:
- 10.1016/j.ijid.2022.11.041
Authors
- Publisher:
- Elsevier
- Journal:
- International Journal of Infectious Diseases More from this journal
- Volume:
- 127
- Article number:
- P11-16
- Place of publication:
- Canada
- Publication date:
- 2022-12-04
- Acceptance date:
- 2022-11-30
- DOI:
- EISSN:
-
1878-3511
- ISSN:
-
1201-9712
- Pmid:
-
36476349
- Language:
-
English
- Keywords:
- Pubs id:
-
1312551
- Local pid:
-
pubs:1312551
- Deposit date:
-
2023-05-24
- ARK identifier:
Terms of use
- Copyright holder:
- Nyagwange et al
- Copyright date:
- 2022
- Rights statement:
- © 2022 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ )
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record